Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares slip overall but German blue-chips hit record high

Fri, 28th Jul 2023 17:31

STOXX 600 dips 0.2% but posts weekly gains

*

Germany's DAX hits record high

*

BOJ policy tweak lifts European yields

*

Capgemini slides as Q2 growth slows

July 28 (Reuters) - European shares retreated from multi-month highs on Friday after a mixed bag of earnings and a surprise Bank of Japan policy tweak, but German blue-chips bucked the trend to close at a record high on signs of cooling inflation.

The pan-European STOXX 600 index ended 0.2% lower after closing at its highest level in nearly 1-1/2 years on Thursday when the European Central Bank hiked interest rates as expected but raised the possibility of a pause in September.

Rattling investor nerves, the BoJ made its yield curve control policy more flexible and loosened its defence of a long-term interest rate cap, in moves seen as a prelude to an eventual shift away from the massive monetary stimulus.

"We have the last of the accommodative central banks moving away from accommodative policies," said Steve Sosnick, chief strategist at Interactive Brokers.

"The fear of this BOJ move was because it can really affect hedge funds' carry trade...there was a fear that this could really spiral out from Japan yields (but) it hasn't happened."

Germany's DAX index hit an intraday record and held on to most of the gains to close 0.39% higher after data showed inflation resumed a downward trend in Europe's largest economy.

However, separate data showed the economy stagnated in the second quarter of 2023, missing forecasts for modest growth

Elsewhere, Spanish consumer prices rose by a more than anticipated 2.3% in the 12 months through July.

Despite Friday's weakness, the benchmark STOXX 600 notched up a third straight week of gains, on hopes that the Federal Reserve and the ECB are nearly done hiking interest rates.

Tech stocks and miners were among the week's top gainers, adding 3.6% and 3.4% respectively.

Hermes rose 3.9% as sales at the Birkin bag maker accelerated in the second quarter, while AstraZeneca advanced 3.3% after reporting forecast-beating profit and sales.

French drugmaker Sanofi slipped 2.9% as quarterly sales fell short of estimates, and French IT consulting group Capgemini tumbled 7.0% on a bigger-than-expected slowdown in second-quarter growth.

Austrian sensor maker AMS Osram jumped 18.5% after the company presented a strategic re-alignment of the group and reported second-quarter results in line with its expectations.

Pan-European stock and derivatives exchange Euronext climbed 7.4%, boosted by the launch of a 200-million-euro ($219.88 million) share buyback programme. (Reporting by Sruthi Shankar, Amruta Khadekar and Shristi Achar A in Bengaluru; Editing by Kirsten Donovan)

More News
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more
12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

Read more
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
10 Jan 2024 06:00

Drugs group Sanofi makes Olympic jump in rebrand bid

LONDON, Jan 10 (Reuters) - Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
21 Dec 2023 15:07

IPO hopes rise for new year after Fed's early holiday gift

LONDON, Dec 21 (Reuters) - Bankers advising companies on stock market listings are hopeful that the new year will bring a recovery in initial public offerings after the U.S. Federal Reserve signalled it may start reversing the fastest escalation in interest rates in decades.

Read more
21 Dec 2023 12:44

IPO hopes rise for new year after Fed's early holiday gift

LONDON, Dec 21 (Reuters) - Bankers advising companies on stock market listings are hopeful that the new year will bring a recovery in initial public offerings after the U.S. Federal Reserve signalled it may start reversing the fastest escalation in interest rates in decades.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
21 Aug 2023 22:37

US FDA approves Pfizer's maternal RSV vaccine to protect infants

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.